<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041379</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069494</org_study_id>
    <secondary_id>LIFETIME-LTP-01-03</secondary_id>
    <nct_id>NCT00041379</nct_id>
  </id_info>
  <brief_title>Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia</brief_title>
  <official_title>Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeTime Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the&#xD;
      immune system and stop cancer cells from growing.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients&#xD;
      who have Waldenstrom's macroglobulinemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor effects of low-dose beta alethine in patients with Waldenstrom's&#xD;
           macroglobulinemia.&#xD;
&#xD;
        -  Determine the effects of this drug on anemia, performance status, and disease symptoms&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the effects of this drug on the immune system of these patients.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive beta alethine subcutaneously on days 1, 15, 29, 43, 57, and 71. Courses&#xD;
      repeat every 85 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 13-37 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2002</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta alethine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of Waldenstrom's macroglobulinemia&#xD;
&#xD;
               -  Urine or serum protein electrophoresis showing a measurable monoclonal spike&#xD;
&#xD;
               -  Indolent disease not yet requiring therapy allowed&#xD;
&#xD;
          -  Positive delayed-type hypersensitivity (DTH) response&#xD;
&#xD;
               -  Induration greater than 2 mm for at least 1 antigen&#xD;
&#xD;
          -  No clinical signs or evidence of active brain involvement or leptomeningeal disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Albumin at least 3.5 g/dL&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No acute changes on EKG&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No heart failure&#xD;
&#xD;
          -  No arrhythmia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Adequate nutritional intake as evidenced by total protein at least 60 g/L&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent gastrointestinal bleed&#xD;
&#xD;
          -  No active bacterial infections such as abscess or with fistulae&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other concurrent non-malignant disease that would preclude study&#xD;
&#xD;
          -  No history of alcoholism, drug addiction, or psychotic disorders that would preclude&#xD;
             follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior cytokines&#xD;
&#xD;
          -  More than 4 weeks since prior plasmapheresis or plasma exchange&#xD;
&#xD;
          -  No prior stem cell or bone marrow transplant&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or&#xD;
             high-dose carboplatin)&#xD;
&#xD;
          -  No prior intensive chemotherapy with stem cell support&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  More than 4 weeks since prior corticosteroids&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy involving more than 25% of bone marrow&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Recovered from any prior surgery&#xD;
&#xD;
          -  No prior organ transplant&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
&#xD;
          -  No concurrent immunosuppressants&#xD;
&#xD;
          -  No concurrent anti-inflammatory agents including aspirin and non-steroidal&#xD;
             anti-inflammatory agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzin Mayerson, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>LifeTime Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Victory Over Cancer</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

